Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 3 1

Status

Completed 12Terminated 5

Sponsor Class

INDUSTRY 5OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Triptorelin Pamoate × Clear all
NCT01673984 2025-05-23

GREAT

Ipsen

Phase 4 Terminated
27 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00415246 2019-11-22

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Ipsen

Phase 3 Terminated
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT00444639 2019-11-22

Study to Assess the Non-inferiority of PamorelinĀ® 11,25mg SC Injected Versus PamorelinĀ® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

Ipsen

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT01374087 2019-09-18

ANABRAQ

Ipsen

Phase 2 Terminated
32 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT02749825 2016-04-25

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Pharmatech

Phase 4 Terminated
41 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔